Grain futures were mostly higher Wednesday on the Chicago Board of Trade. Dec. corn lost 0.75 cent at $4.49 a bushel. Dec. wheat gained 8.25 cents at $6.01 a bushel. Dec. oats was up ...
Tech Times on MSN
One-shot gene therapy cuts dangerous triglycerides 63%: Permanent edit needs no refills
CRISPR therapy CTX310 reduced triglycerides 63% in a Phase 1b trial for severe hypertriglyceridemia, pointing to a potential ...
ORLANDO -- Rheumatoid arthritis (RA) may not be as amenable to chimeric antigen receptor (CAR) T-cell therapy as has been the ...
A joint clinical practice guideline evaluates surgical and ablative treatment options for patients with drug-resistant ...
Innovent Biologics announced that its Phase 3 CREDIT-5 study met its primary endpoint, demonstrating potent lipid-lowering ...
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...
Clinicians report a fatal case of mixed invasive fungal pneumonia involving Aspergillus, Candida, and Mucor in an ...
ARO-DIMER-PA, Arrowhead Pharmaceuticals’ investigational dual-gene RNAi drug, posted 54% LDL cholesterol and 73% triglyceride ...
Target RNA Therapy that targets the liver to lower two key proteins involved in high cholesterol at the same time ...
There is still no law that clearly defines self-pay rehabilitation. For this reason, if you are providing it in a medical ...
On November 3, 2026, the United States Food and Drug Administration (FDA) finalized its December 2023 draft guidance Potency Assurance for ...
The FDA granted accelerated approval to subcutaneous amivantamab and hyaluronidase (Rybrevant Faspro) for the treatment of adults with recurrent or metastatic head and neck squamous cell carcinoma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results